Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease

Exclusion Criteria

• •（ - ） History of excessive alcohol consumption (alcohol consumption equivalent to ethanol \> 30 g/d for males and \> 20 g/d for females);
• •（ - ） End-stage liver disease (e.g. hepatic cirrhosis or hepatic cancer) or other conditions which may lead to fatty liver;
• •（ - ） Unable to cooperate to complete MR examination;
• •（ - ） Subjects who have used any nonsteroidal anti-inflammatory drug or corticosteroid in the past month;
• •（ - ） Patients with iron deficiency or iron deficiency anemia;
• •（ - ） ALT or AST increased to 8 × upper limit of normal (ULN), and bilirubin increased to 2×ULN;
• •（ - ） Patients with coagulation disorder or haemorrhagic diathesis (platelets \<100×109/L);
• •（ - ） Patients with duodenal ulcer, or previous or existing pancreatitis;
• •（ - ） History of liver abscess;
• •（ - ） History of gallstones (symptomatic or presenting of any stone with a diameter greater than 20mm);
• •（ - ） Patients with gastrointestinal hemorrhage or potential hemorrhage;
• •（ - ） Gastrointestinal tract anomalies, such as gastrointestinal tract atresia or any or other conditions that would result in failed placement in the gastrointestinal tract;
• •（ - ） Patients with history of intestinal obstruction or related disease in the past year;
• •（ - ） Drug abusers or patients with uncontrollable psychiatric disorders;
• •（ - ） Patients with any contraindication to endoscopy based on the investigator's judgment;
• •（ - ） Pregnancy or lactating women;
• •（ - ） Patients who are participating in any other drug or medical device clinical study;
• •（ - ） Patients with any other conditions evaluated by the investigators as unsuitable for participating in the trial;